There is growing evidence that the function of ovarian thecainterstitial (T-I) cells may be modulated by paracrine actions of activin, inhibin, and follistatin. Furthermore, either dysregulation, dysfunction, or both, of these peptides may play a role in conditions associated with T-I hyperplasia, such as polycystic ovary syndrome (PCOS) and hyperthecosis. This study was designed to evaluate the role of activin, inhibin, and follistatin in the modulation of T-I cell proliferation. Interaction of these peptides with insulin-like growth factor-I (IGF-I), a known stimulator of T-I cell proliferation, was also assessed. Purified rat T-I cells were cultured for 48 h in chemically defined media and with or without activin (3-30 ng/ml), inhibin (3-30 ng/ml), follistatin (100 ng/ml), and/or IGF-I (10 nM). T-I cell proliferation was assessed using radiolabeled thymidine incorporation assay. Activin alone stimulated proliferation of T-I cells in a dose-dependent fashion (by up to 320% above control; P Ͻ 0.001), whereas inhibin alone or follistatin alone had no significant effect. Inhibin had also no effect on activin-induced proliferation. Follistatin significantly reduced the stimulatory effects of activin and decreased proliferation by up to 46% (P Ͻ 0.01) below the level attained in the presence of activin alone. IGF-I (10 nM), at a dose producing a near-maximal effect, increased proliferation by 175% above control (P Ͻ 0.001); insulin (10 nM) increased proliferation by 52% above control (P Ͻ 0.03). A combination of IGF-I (10 nM) and activin (30 ng/ml) resulted in a 1090% increase of proliferation above control (P Ͻ 0.001); this stimulatory effect was significantly greater than that achieved in the presence of either activin alone or IGF-I alone (P Ͻ 0.001). Similarly, a combination of insulin (10 nM) and activin (30 ng/ ml) increased proliferation by 506% above control levels. Flow cytometry evaluation revealed that activin increased the proportion of actively dividing cells (in S or G2/M phase of the cell cycle) by 42% (P Ͻ 0.02), whereas IGF-I had no effect on the proportion of actively dividing cells. The present findings indicate that an activin-follistatin system may be involved in the regulation of the size of ovarian thecal-stromal compartment. In view of the synergy between activin and IGF-I, and the difference in the effects on the cell cycle distribution, stimulation of T-I proliferation by these agents is likely to be mediated via separate transduction pathways. Excess activin or insufficient follistatin may contribute to T-I hyperplasia.
INTRODUCTION
Activin, inhibin, and follistatin form an interactive system of glycoproteins that exert a broad range of endocrine, paracrine, and autocrine effects, including modulation of proliferation and differentiation of various tissues. These glycoproteins, originally detected within the ovary, were subsequently identified in various other organs [1] [2] [3] . Activin interacts with target cells by binding to type I and type II activin receptors [4] . Inhibin binds to type II activin receptors, possibly in competition with activin; however, a recent study presented evidence for an inhibin-binding protein that is distinct from proteins that bind activin [5] . In many systems, the effects of inhibin are the opposite of those of activin. Follistatin may attenuate the effects of activin by binding to its ␤ subunit, thus preventing activin from accessing its receptors.
There is growing evidence that an activin-inhibin-follistatin system plays an important role in the regulation of ovarian function, including follicular development, atresia, and steroidogenesis [6] [7] [8] . Administration of activin in vivo increases the number of large follicles and induces premature superovulation [9] . Activin also acts directly on granulosa and thecal-interstitial (T-I) cells. In granulosa cell cultures, activin augments aromatase activity, inhibits progesterone production, increases expression of FSH receptors, and stimulates mitogenic activity [10] [11] [12] [13] [14] . Steroidogenic effects of activin on granulosa cells are blocked by follistatin [15] . In theca cell cultures, most but not all studies have indicated that activin inhibits androgen production [16] [17] [18] . Inhibin has the opposite effects of activin on thecal androgen production and blocks activin-induced effects [16, 19, 20] .
The activin-inhibin-follistatin system has been also implicated in the pathophysiology of polycystic ovary syndrome (PCOS) [2, 17, [21] [22] [23] . PCOS is characterized by oligo-anovulation and hyperandrogenism associated with increased ovarian androgen production. A linkage between PCOS and follistatin has also been recently demonstrated in an elegant population genetics study [23] . The authors proposed that PCOS may be associated with an increased availability of follistatin and thus attenuated activity of activin. Such a concept is supported by in vitro studies demonstrating inhibition of thecal androgen production by activin [16, 20] . However, these observations are difficult to reconcile with the evidence for an increased availability of activin in follicles from patients with PCOS in comparison to follicles from normal ovaries [2] . This increase of activin may be due in part to decreased expression of the inhibin alpha subunit and follistatin mRNA in PCOS follicles [2] . Ultimately, the role of activin and follistatin in the pathophysiology of PCOS remains unclear.
One of the hallmarks of PCOS is ovarian stromal and thecal hyperplasia [24, 25] . Our recent studies have demonstrated that excessive growth of ovarian T-I cells may be due to proliferative effects of insulin, insulin-like growth factors (IGFs), or both [26] [27] [28] . Others have shown that activin may modulate proliferative effects of IGFs in various tissues [29] [30] [31] . In view of the above studies, we hypothesized that the activin-inhibin-follistatin system is involved in the regulation of proliferation of ovarian mesenchyme.
MATERIALS AND METHODS

Materials
The following materials were purchased from Sigma Chemical Co. (St. Louis, MO): medium-199 with Hank balanced salt solution (HBSS), medium 199 with HBSS (10ϫ), McCoy 5a medium (modified, without serum), L-glutamine, BSA, trypsin-EDTA (0.05%/0.02%), nitro-blue tetrazolium, 5␤-androstan-3␤-ol-17-one, ␤-NADϩ, sesame oil, Percoll, recombinant IGF-I, Hoechst 33342, and DiOC 5 . Collagenase type I (Clostridium histolyticum, CLS1; 146 U/mg) and DNase I (bovine pancreas; 2298 U/ mg) were obtained from Worthington Biochemical Co. (Freehold, NY). The following materials were purchased from Grand Island Biological Co. (Grand Island, NY): trypan blue stain (0.4%; wt/vol), antibiotic-antimycotic preparation (penicillin, 10 000 IU/ml; streptomycin, 10 000 g/ml; amphotericin B, 25 g/ml), and Dulbecco (1ϫ pH 7.2, without MgCl 2 and CaCl 2 ). HEPES was purchased from American Bioanalytical (Natick, MA). Radiolabeled 
Animals
Immature (25-day-old) female Sprague-Dawley rats were obtained from Taconic Farms (Germantown, NY) and housed with a 12L:12D photoperiod in an air-conditioned environment. Standard rat chow and water were given ad libitum. Starting on the 28th day of age, the animals were injected with 17␤-estradiol (1 mg/0.3 ml sesame oil s.c.) daily for 3 days in order to stimulate ovarian development. This treatment yields ovaries with medium-size follicles and actively dividing T-I cells [32] . On the morning following the last injection (Day 31 of age), the animals were anesthetized with ketamine and xylazine (i.p.) and killed by perfusion with 0.9% saline. All treatments and procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and a protocol approved by the Yale University Animal Care Committee.
Isolation of T-I Cells and Cell Cultures
Ovaries were dissected, and T-I cells were isolated and purified as described previously [26] . Briefly, ovarian follicles were punctured to release most of the granulosa cells; the remaining ovarian tissues were enzymatically digested, washed, and separated using a Percoll gradient. Each ovary yielded approximately 400 000-600 000 T-I cells. The purity of this preparation was reported previously [26] . Briefly, before plating, 95.4% of cells stained positive for a mesenchymal marker, vimentin; 7.6% of cells stained positive for an epithelial marker, cytokeratin; and 2.2% of cells stained positive for an endothelial marker, factor VIII. The cells were counted using a hemocytometer and viability was determined using a Trypan blue stain exclusion test. Cell viability was in the 85% to 95% range. The cells were cultured in McCoy 5a medium supplemented with L-glutamine (2 mM), BSA (1 mg/ml), penicillin (10 000 IU/ml), streptomycin (10 000 g/ml), and amphotericin B (25 g/ml). Cultures were carried out at 37ЊC in an atmosphere of 5% CO 2 
DNA Synthesis Determination
Radiolabeled [ 3 H]thymidine (1 Ci/well) was added to cultured T-I cells during the last 24 h of culture. At the end of the culture period, the cells were harvested using a multiwell cell harvester (PHD Harvester Model 290, Cambridge Technology, Inc., Watertown, MA). Radioactivity was measured in a liquid scintillation counter, SL 4000 (Intertechnique, Fairfield, NJ). Each treatment was carried out in at least six replicates.
Flow Cytometry Analysis of Cell Cycle
The assessment of the cell cycle distribution was performed by flow cytometry of propidium iodide (PI) stained T-I cells following a modified method described by others [33] . In order to maximize the number of viable cells for flow cytometry analysis, T-I cells were cultured in McCoy 5a medium supplemented with FBS (10%) for 24 h. Subsequently, the cells were washed with serum-free McCoy 5a medium and cultured for 24 h in fresh McCoy 5a serum-free medium with or without activin, IGF-I, or both. At the end of the culture period, the cells were dispersed with the aid of trypsin-EDTA solution, washed, resuspended in 2 ml of icecold PBS, and fixed by three stepwise additions of 2 ml each of 95% icecold ethanol. The fixed T-I cells were stored at 4ЊC awaiting flow cytometry analysis. On the day of analysis the T-I cells were spun down and resuspended in ribonuclease solution (1 mg/ml in PBS, pH 7.0) for 30 min at 37ЊC, and subsequently treated with PI (0.05 mg/ml) for 1 h. Prior to analysis the samples were filtered through 35-micron nylon mesh (TET-KO Inc., Elmsford, NY). Flow cytometric analysis was performed with a FACS Vantage flow cytometer (Becton Dickinson Immunocytometry Systems). The cells were excited with an argon laser operating at 488 nm. PI fluorescence was collected in a linear mode through a 630/22 nm band pass filter. At least 15 000 cells were analyzed for each sample. Cell cycle analysis was performed using the Modfit 5.2 multitrapezoid model (Verity Software House, Topsham, ME). The results were expressed as the proliferative index (the sum of percentages of cells in S and G 2 /M phases of the cell cycle obtained from DNA histograms). Each treatment was carried out in at least four replicates.
General Considerations and Statistical Analysis
In each experiment ovaries were pooled from 10 to 12 rats. Individual experiments were repeated at least twice; results of representative experiments are presented.
Results are presented as the mean Ϯ SEM. Comparisons between the means were performed using ANOVA followed by post-hoc comparisons of individual means using Bonferroni correction. Differences were considered significant at P Ͻ 0.05.
RESULTS
DNA Synthesis
DNA synthesis was evaluated by quantifying [ 3 H]thymidine incorporation. Activin (1-30 ng/ml) produced a dosedependent increase in DNA synthesis by up to 322% above control levels (Fig. 1) . In order to determine whether the ef- fects of activin were modulated by follistatin, T-I cells were cultured with or without follistatin (100 ng/ml), activin (3 or 30 ng/ml), or both. As demonstrated in Figure 2 , follistatin alone had no significant effect on DNA synthesis; however, follistatin significantly decreased activin-induced DNA synthesis (by 37% and 46% for activin at 3 and 30 ng/ml, respectively). Figure 3 presents effects of IGF-I and insulin on basal and activin-induced DNA synthesis. IGF-I (10 nM) alone increased DNA synthesis by 175% above the control. Insulin (10 nM) alone increased DNA synthesis by 52% above the control. When the cells were exposed simultaneously to IGF-I and activin, the radiolabeled thymidine incorporation increased by 1090% above control levels, indicating that IGF-I and activin produced a synergistic effect on DNA synthesis. In a similar fashion, insulin in combination with activin increased radiolabeled thymidine incorporation by 506% above control levels. Figure 4 summarizes the experiment determining radiolabeled thymidine incorporation in the presence or absence of inhibin (30 ng/ml), IGF-I (10 nM), activin (30 ng/ml), or a combination of these. Inhibin (3-30 ng/ml) had no significant effect on basal DNA synthesis. Furthermore, inhibin had no effect on activin-or IGF-I-induced DNA synthesis. Notably, in the above-tested system there was no positive control for the bioactivity of the inhibin preparation. Figure 5 summarizes the effects of activin (30 ng/ml) and IGF-I (10 nM) on cell cycle progression of cultured T-I cells. Activin alone significantly increased the proportion of proliferating cells, as reflected by a 65% increase in the proliferative index. In contrast, IGF-I had no significant effect on basal or activin-induced proliferative index.
Determination of the Proliferative Index by Flow Cytometry
DISCUSSION
To our knowledge, this is the first report evaluating the effects of activin on proliferation of ovarian mesenchyme. We have shown that 1) activin stimulates proliferation of T-I cells in a dose-dependent fashion; 2) follistatin attenuates activin-induced proliferation; 3) the effects of activin are synergistic with IGF-I and insulin; and 4) activin acts, at least in part, by increasing the proportion of actively dividing cells. The present findings support the notion that an activin-follistatin system may be relevant in the regulation of ovarian growth and folliculogenesis. Indeed, several in vitro studies have shown that activin promoted follicular development, whereas follistatin blocked this effect [34, 35] . Furthermore, administration of follistatin vaccine to heifers resulted in an increase in the number of ultrasonographically detectable follicles [36] . Because follicular development requires proliferation of theca cells, the balance between activin and follistatin may be important in the paracrine and/or autocrine regulation of folliculogenesis.
Activin, inhibin, and follistatin are produced predominantly by granulosa cells [2, 37, 38] . In theca cells, follistatin and the beta A subunit of activin were detected; however, there was no evidence of gene expression for these proteins [37] . The above observations indicate that follistatin and activin may act on theca cells as paracrine agents. Mounting evidence indicates that in the course of follicular development, the relative levels of activin, relative to inhibin, decreases; furthermore, increased production of follistatin in preovulatory follicles further limits effects of activin [39] . These events may be responsible for the regulation of thecal steroidogenesis and growth; specifically, as the follicle matures, the decrease of activin may lead to decreased thecal growth and increased androgen production [16] .
The lack of significant fluctuations in the levels of activin and follistatin during the menstrual cycle argues against a significant endocrine role for these peptides in adult women [40, 41] . However, it is possible that activin may be relevant as an endocrine and local regulator of ovarian growth before and during puberty. This concept is supported by the evidence that at puberty, serum follistatin levels are lower than in adulthood [42] , indicating thus, that during the period of intense ovarian growth, there may be greater availability of biologically active activin. In addition, the immature ovary may be more sensitive to the effects of activin; for example, activin has been shown to promote folliculogenesis in cultures of follicles from immature, but not adult, mice [43] .
Activin and follistatin may also play a role in the pathophysiology of conditions such as hyperthecosis and PCOS. These disorders are characterized by prominent hyperplasia of ovarian stroma and theca [24, 25] . The present study provides arguments for the hypothesis that either increased availability of activin, or decreased follistatin (or both) may contribute to excessive growth of ovarian thecal and stromal compartments. This hypothesis is further supported by the findings of Roberts et al. [2] , who demonstrated that expression of follistatin mRNA is lower in granulosa cells from polycystic ovaries. In addition, there is evidence suggesting a linkage between PCOS and the follistatin gene [23] . Excessive growth of ovarian mesenchyme may also be due to a synergy between activin with insulin and IGF-I. Women with PCOS have typically significant hyperinsulinemia and elevated, free, bioavailable IGF-I [44] [45] [46] [47] . In these patients, insulin and IGF-I may excessively amplify the proliferative actions of activin.
Synergy between the proliferative effects of activin and insulin/IGF-I indicates that the mechanisms of action of these agents on proliferation of T-I cells are independent. Our previous dose-response experiments have demonstrated that a near-maximal stimulation of proliferation occurs at a dose of 10 nM IGF-I [26] . In the present study, the effect of this dose of IGF-I has been amplified by activin by more than sixfold. Furthermore, our flow cytometry data demonstrate that activin promotes proliferation, at least in part, by increasing the proportion of actively dividing T-I cells (cells in S and G 2 /M phases of the cell cycle). In contrast, IGF-I has no significant effect on the distribution of cells throughout the cell cycle. A plausible explanation of this observation may be that agents such as IGF-I can accelerate the progression through the cell cycle without affecting the proportion of dividing cells, whereas activin increases the pool of the dividing cells. Thus, activin may act, at least in part, as a competence factor. It should be noted that the T-I cells represent not a pure population of uniform cells, but an enriched preparation of theca externa, theca interna, and stromal cells. It is possible that IGF-I and activin may promote proliferation of separate subpopulations of cells; however, in that case, additive rather than synergistic effects would be more likely. The lack of the effect of IGF-I on the proportion of the dividing cells may be also due to experimental conditions; in this study, effects of IGF-I were observed only at a single time point. Review of the literature indicates that the effects of IGF-I and insulin on the cycling fraction of cells depend on the tissue source; for example, these agents increased the cycling fraction of Swiss 3T3 cells, but not human fibroblasts [48] .
Effects of activin on proliferation may be tissue-dependent and possibly species-dependent. In previous studies, activin inhibited proliferation of many cell types, including rat pituitary somatotrophs, human pituitary tumors, insulinproducing INS-1 cells, rat thymocytes, LNCaP prostatic cancer cells, and human hepatocytes [49] [50] [51] [52] [53] [54] . In contrast, activin stimulated proliferation of many other cells, including 3T3 fibroblasts, rat vascular smooth muscle, and avian premyocardial cells [30, 31, 52] . The effects of activin on gonadal tissues are also mixed. Thus, activin stimulated proliferation of Sertoli cells but inhibited proliferation of spermatogonia [55] . In the ovary, both stimulation and inhibition of granulosa cell proliferation by activin was reported [10, 56] . Activin also increased proliferation of several human ovarian cancer cell lines but decreased growth of Chinese hamster ovary cells [57, 58] . These divergent observations raise an interesting question: What are the characteristics predisposing given tissues to increase or decrease proliferation in response to activin? Although no clear answer is apparent, it is interesting to note that activin appears to consistently stimulate proliferation in fibroblasts and fibroblast-related tissues, including the T-I cells.
T-I cells, fibroblasts, and other fibroblast-related cells, such as vascular smooth muscle, also have similar proliferative responses to insulin and IGF-I [26, 30, 32, 59, 60] . In a similar fashion to presently observed effects on T-I cells, activin has also been shown to potentiate proliferative effects of IGF-I in cultures of vascular smooth muscle [30] .
In summary, we propose that an activin-follistatin system may play a role in the regulation of growth of ovarian thecal and stromal compartments, and that under pathological conditions, dysregulation of this activin-follistatin system may lead to excessive growth of the ovarian mesenchyme.
